Latest IPO / New Healthcare Listings

Asep Medical Engages Aegis Capital Corporation for Listing on NASDAQ Stock Exchange

May 30
Last Trade: 0.40 0.09 29.03

VANCOUVER, BC, May 30, 2023 /CNW/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that it has engaged Aegis Capital Corporation ("Aegis"), a New York-based investment bank, as underwriter agent for a proposed listing on the NASDAQ Stock Exchange (the "Offering"). The Offering is expected to consist of a sale of the minimum requirement needed to be...Read more

MindBio Therapeutics Lists Common Shares on Canadian Securities Exchange

May 5
Last Trade: 0.07 -0.005 -6.67

Leading biotech/biopharm company MindBio lists on the Canadian Securities Exchange Psychedelic medicine fund, Negev Capital is a shareholder Successful completion of Phase 1 trial and two fully funded Phase 2 trials begin shortly World first take-home approvals for LSD-Microdosing clinical trials. VANCOUVER, BC / ACCESSWIRE / May 5, 2023 / MindBio Therapeutics Corp. (CSE:MBIO); (the "Company" or "MindBio") is pleased to...Read more

Johnson & Johnson and Kenvue Announce Pricing of Upsized Initial Public Offering

May 3
Last Trade: 156.97 2.43 1.57

NEW BRUNSWICK, N.J. & SKILLMAN, N.J. / May 03, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue’s upsized initial public offering (“IPO”) of 172,812,560 shares of Kenvue’s common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to...Read more

Johnson & Johnson Announces Launch of Kenvue IPO Roadshow

April 24
Last Trade: 156.97 2.43 1.57

NEW BRUNSWICK, N.J. / Apr 24, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (“IPO”) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its...Read more

Ambrx Biopharma to Commence Trading on Nasdaq

March 6
Last Trade: 14.92 0.39 2.68

SAN DIEGO / Mar 06, 2023 / Business Wire / Ambrx Biopharma Inc. (NYSE: AMAM) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx’s American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker...Read more

Field Trip Health & Wellness Announces Posting on the OTC Market

February 3
Last Trade: 0.06 0.00 0.00

TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), global leader in the delivery of psychedelic therapies, is pleased to announce that the Company has received approval from the Financial Regulatory Authority (“FINRA”) for its shares to commence trading on the OTCQB Market (“the OTCQB”) in the United States under the symbol “FTHWF” effective February 2, 2023....Read more

SANUWAVE Health Commences Trading on the OTCQB Under Ticker Symbol SNWV

January 30
Last Trade: 0.02 -0.0006 -3.73

EDEN PRAIRIE, MN, Jan. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (OTCQB: SNWV) (“SANUWAVE”), a leading provider of next-generation FDA-approved wound care products, is pleased to announce that its common stock commenced trading on the OTCQB today. About SANUWAVE SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological...Read more

Medigus: Eventer Technologies Signed a Definitive Agreement for Reverse Merger to Become a Public Company

January 9
Last Trade: 4.60 0.25 5.75

Eventer will merge with a Tel-Aviv Stock Exchange listed company following which Eventer shareholdres will hold 74.99% of the merged company Tel Aviv, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that its 46.21% owned subsidiary, Eventer Technologies...Read more

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

January 9
Last Trade: 0.13 0.00 0.00

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) formed for the purpose of acquiring or merging with one or more businesses (“Newcourt” or the “Company”), today...Read more

Lipella Pharmaceuticals Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million

December 22
Last Trade: 1.94 0.03 1.57

PITTSBURGH, Dec. 22, 2022 /PRNewswire/ — Lipella Pharmaceuticals Inc. ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced the closing of its initial public offering of 1,217,391 shares of its common stock at a price to the public of $5.75 per...Read more

Kineta Completes Reverse Merger with Yumanity Therapeutics

December 19
Last Trade: 3.00 0.00 0.00

Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA — (December 19, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse merger with Yumanity Therapeutics, Inc. (“Yumanity”). The combined company will operate...Read more

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

December 13
Last Trade: 0.80 0.00 0.00

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today. As announced and previously approved by shareholders on December 7,...Read more

ZyVersa Therapeutics and Larkspur Health Acquisition Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022

December 12
Last Trade: 0.38 -0.04 -8.54

ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J., Dec. 12, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with renal or inflammatory...Read more

Sign Up To Get Daily Health Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...